Key clinical point: Hepatocellular carcinoma patients with intermediate or advanced disease experienced significantly improved outcomes when treated with transarterial chemoembolization (TACE) plus sorafenib vs. TACE only.
Major finding: Patients treated with TACE plus sorafenib showed a significant increase in average progression-free survival and overall survival compared to those treated with TACE only (21 months vs. 12 months and 32 months vs. 21 months, respectively).
Study details: The data come from a retrospective review of 85 adults with intermediate or advanced HCC who were treated with transarterial chemoembolization (TACE) alone or with sorafenib.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Zou X et al. Cancer Manag Res. 2021 May 18. doi: 10.2147/CMAR.S304591.